Open AccessImmunogenicity Study of Glycoprotein-Deficient Rabies Virus Expressing Simian/Human Immunodeficiency Virus SHIV89.6PEnvelope in a Rhesus Macaque
Author(s) -
Philip M. McKenna,
Pyone P. Aye,
Bernhard Dietzschold,
David C. Montefiori,
Louis N. Martin,
Preston A. Marx,
Roger J. Pomerantz,
Andrew A. Lackner,
Matthias J. Schnell
Publication year - 2004
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.78.24.13455-13459.2004
Subject(s) - virology , biology , simian immunodeficiency virus , immunogenicity , rhesus macaque , simian , rabies virus , macaque , glycoprotein , virus , lyssavirus , viral envelope , rhabdoviridae , rabies , immunology , antibody , microbiology and biotechnology , paleontology
Rabies virus (RV) has recently been developed as a novel vaccine candidate for human immunodeficiency virus type 1 (HIV-1). The RV glycoprotein (G) can be functionally replaced by HIV-1 envelope glycoprotein (Env) if the gp160 cytoplasmic domain (CD) of HIV-1 Env is replaced by that of RV G. Here, we describe a pilot study of the in vivo replication and immunogenicity of an RV with a deletion of G (DeltaG) expressing a simian/human immunodeficiency virus SHIV(89.6P) Env ectodomain and transmembrane domain fused to the RV G CD (DeltaG-89.6P-RVG) in a rhesus macaque. An animal vaccinated with DeltaG-89.6P-RVG developed SHIV(89.6P) virus-neutralizing antibodies and SHIV(89.6P)-specific cellular immune responses after challenge with SHIV(89.6P). There was no evidence of CD4(+) T-cell loss, and plasma viremia was controlled to undetectable levels by 6 weeks postchallenge and has remained suppressed out to 22 weeks postchallenge.